Biopharmaceutical Company SutroVax Raises $22 million in Series A Funding Round Led By International Investment Group Abingworth
SutroVax, a recently established biopharmaceutical vaccine company, announced on Thursday the completion of a $22 million Series A financing round. This round was led by Abingworth, the international investment group, with participation from Longitude Capital, Roche Venture Fund and CTI Life Sciences Fund. SutroVax is developing vaccines… Read More